<DOC>
	<DOCNO>NCT01393964</DOCNO>
	<brief_summary>The purpose study assess concentration Elotuzumab Myeloma patient low kidney function include patient dialysis .</brief_summary>
	<brief_title>Study Elotuzumab Combination With Lenalidomide Dexamethasone Subjects With Multiple Myeloma Various Levels Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects Multiple Myeloma ( MM ) renal function fit one three category : 1 . Severe renal impairment : estimate creatinine clearance ( CrCl ) &lt; 30 ml/min , require dialysis 2 . Endstage renal disease : require hemodialysis 3 . Normal renal function : estimate CrCl ≥90 ml/min Documented evidence symptomatic MM , either newly diagnose relapsed/refractory Prior Lenalidomide exposure permit subject discontinue Lenalidomide due Grade ≥3 related Adverse Event ( AE ) Monoclonal Gammopathy Undetermined Significance ( MGUS ) , Waldenstrom 's macroglobulinemia , smolder myeloma Active plasma cell leukemia All adverse event prior chemotherapy , surgery , radiotherapy resolve POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Acute renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>